Page 1,066«..1020..1,0651,0661,0671,068..1,0801,090..»

UC San Diego to advance stem cell therapies in new space station lab – – KUSI

Posted: April 11, 2020 at 8:41 pm

April 9, 2020

Posted: April 9, 2020

Updated: 5:22 PM

KUSI Newsroom

SAN DIEGO (KUSI) UC San Diego and Space Tango receive NASA award to develop first dedicated stem cell research laboratory within the International Space Station.

UCSDs website reports, A three-year, nearly $5 million award from NASA will allow researchers at the Sanford Stem Cell Clinical Center at UC San Diego Health, Sanford Consortium for Regenerative Medicine and their partners at Space Tango to develop a new integrated space stem cell orbital research laboratory within the International Space Station (ISS) and launch three collaborative research projects within it.

Stem cells self-renew, generating more stem cells, and specialize into tissue-specific cells, such as blood, brain and liver cells, making them ideal for biological studies far from Earths resources. The goal of the new effort is to leverage microgravity and these unique properties of stem cells to better understand how space flight affects the human body. The studies will also inform how aging, degenerative diseases, cancers and other conditions develop in a setting with increased exposure to ionizing radiation and pro-inflammatory factors. The findings from these studies may speed the development of new therapeutics for a broad array of degenerative diseases on Earth.

Dr. Catriona Jamieson, the lead researcher on this NASA award story, visited KUSI News to tell us all about it.

For more information, click here.

Original post:
UC San Diego to advance stem cell therapies in new space station lab - - KUSI

Posted in Stem Cell Research | Comments Off on UC San Diego to advance stem cell therapies in new space station lab – – KUSI

Insights on the Worldwide Human Embryonic Stem Cells Market to 2025 – Rising Demand for Regenerative Medicines Presents Opportunities -…

Posted: April 11, 2020 at 8:41 pm

DUBLIN--(BUSINESS WIRE)--The "Human Embryonic Stem Cells Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

The government funding for the development of regenerative medicine has been increasing in most developed countries, because of its applications in organ transplantation, tissue engineering, and various other applications. In the United States, two major government agencies, National Institutes of Health (NIH) and California Institute of Regenerative Medicine (CIRM), fund almost all the translational researches and regenerative medicine development in the country.

It is estimated that the United States government invests around USD 800-900 million every year in stem cell research. Additionally, other factors such as the high prevalence of cardiac and malignant diseases, and rising demand for regenerative medicines are expected to drive the market.

Key Market Trends

Stem Cell Biology Research Segment is Expected to Show Better Growth in the Forecast Years

Based on the application, it is segmented into regenerative medicine, stem cell biology research, tissue engineering, and toxicology testing. Stem cell biology research will show better growth, owing to the high prevalence of cardiac and malignant diseases. An article published by the ISSCR (International Society for Stem Cell Research) reported that the stem cells hold potential for the treatment of Parkinson's disease in humans. Recently, one of the market players, International Stem Cell Corporation (ISCO), received the patent covering methods for generating HLA homozygous parthenogenetic human stem cell lines from unfertilized eggs. The patent was issued in Australia. Furthermore, to boost the pace of stem cell research, the government is providing funding opportunities to researchers. Thus, owing to these factors, the market studied is expected to witness a high growth rate over the forecast period.

North America Dominates the Human Embryonic Stem Cells Market

The human embryonic stem cells market is expected to dominate in the North America region owing to extensive research activities, along with high burden of chronic diseases and genetic disorders in the region. The United States also shows a high incidence of other diseases, such as diabetes, heart disease, renal failure, and osteoporosis. Human embryonic stem cells have high potential for use in treatment and may become a standard of care for these diseases. Additionally, the FDA has approved clinical trials, which indicated the use of stem cells. Hence, these factors are expected to influence the growth of the human embryonic stem cells market over the forecast period.

Competitive Landscape

The global players into the human embryonic stem cells market are Becton, Dickinson and Company, Cynata Therapeutics Limited, ESI BIO, Geron Corporation, International Stem Cell Corporation, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc, Thermo Fisher Scientific and ViaCyte, Inc.

Key Topics Covered:

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 High Prevalence of Cardiac and Malignant Diseases

4.2.2 Rising Demand for Regenerative Medicines

4.2.3 Increasing Support from Governments and Government and Private Institutions

4.3 Market Restraints

4.3.1 High Cost of the Procedure

4.3.2 Stringent Regulatory Guidelines

4.4 Porter's Five Forces Analysis

4.4.1 Threat of New Entrants

4.4.2 Bargaining Power of Buyers/Consumers

4.4.3 Bargaining Power of Suppliers

4.4.4 Threat of Substitute Products

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Application

5.1.1 Regenerative Medicine

5.1.2 Stem Cell Biology Research

5.1.3 Tissue Engineering

5.1.4 Toxicology Testing

5.2 Geography

5.2.1 North America

5.2.1.1 United States

5.2.1.2 Canada

5.2.1.3 Mexico

5.2.2 Europe

5.2.2.1 Germany

5.2.2.2 United Kingdom

5.2.2.3 France

5.2.2.4 Italy

5.2.2.5 Spain

5.2.2.6 Rest of Europe

5.2.3 Asia-Pacific

5.2.3.1 China

5.2.3.2 Japan

5.2.3.3 India

5.2.3.4 Australia

5.2.3.5 South Korea

5.2.3.6 Rest of Asia-Pacific

5.2.4 Rest of World

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Becton, Dickinson and Company

6.1.2 Cynata Therapeutics Limited

6.1.3 ESI BIO

6.1.4 Geron Corporation

6.1.5 International Stem Cell Corporation

6.1.6 Merck KGaA

6.1.7 PromoCell GmbH

6.1.8 STEMCELL Technologies Inc

6.1.9 Thermo Fisher Scientific

6.1.10 ViaCyte, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/ayr2ww

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more here:
Insights on the Worldwide Human Embryonic Stem Cells Market to 2025 - Rising Demand for Regenerative Medicines Presents Opportunities -...

Posted in Stem Cell Research | Comments Off on Insights on the Worldwide Human Embryonic Stem Cells Market to 2025 – Rising Demand for Regenerative Medicines Presents Opportunities -…

Hematopoietic Stem Cell Transplantation (HSCT) Market Information, Figures and Analytical Insights 2019 2025 – Germany English News

Posted: April 11, 2020 at 8:41 pm

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Hematopoietic Stem Cell Transplantation (HSCT) Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Hematopoietic Stem Cell Transplantation (HSCT) market. We have also provided absolute dollar opportunity and other types of market analysis on the global Hematopoietic Stem Cell Transplantation (HSCT) market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Hematopoietic Stem Cell Transplantation (HSCT) market. All findings and data on the global Hematopoietic Stem Cell Transplantation (HSCT) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Hematopoietic Stem Cell Transplantation (HSCT) market available in different regions and countries.

Request Sample Report @https://www.mrrse.com/sample/9594?source=atm

The authors of the report have segmented the global Hematopoietic Stem Cell Transplantation (HSCT) market as per product, application, and region. Segments of the global Hematopoietic Stem Cell Transplantation (HSCT) market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Hematopoietic Stem Cell Transplantation (HSCT) market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

Companies Mentioned in the Report

The report profiles key manufacturers in the hematopoietic stem cell transplantation (HSCT) Market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include Regen Biopharma, Inc., Escape Therapeutics, Inc., Lonza Group Ltd., and Pluristem Therapeutics Inc.

The global hematopoietic stem cell transplantation (HSCT) Market has been segmented as follows:

By Transplant Type

By Disease Indication

By Application

By Region

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/9594?source=atm

Hematopoietic Stem Cell Transplantation (HSCT) Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Hematopoietic Stem Cell Transplantation (HSCT) Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Hematopoietic Stem Cell Transplantation (HSCT) Market in South, America region is also expected to grow in near future.

The Hematopoietic Stem Cell Transplantation (HSCT) Market report highlights is as follows:

This Hematopoietic Stem Cell Transplantation (HSCT) market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Hematopoietic Stem Cell Transplantation (HSCT) Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Hematopoietic Stem Cell Transplantation (HSCT) Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Hematopoietic Stem Cell Transplantation (HSCT) Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

Buy This Report @ https://www.mrrse.com/checkout/9594?source=atm

Go here to read the rest:
Hematopoietic Stem Cell Transplantation (HSCT) Market Information, Figures and Analytical Insights 2019 2025 - Germany English News

Posted in Stem Cell Research | Comments Off on Hematopoietic Stem Cell Transplantation (HSCT) Market Information, Figures and Analytical Insights 2019 2025 – Germany English News

Hackensack Meridian Health Studying the Blood of COVID-19 Survivors – P&T Community

Posted: April 11, 2020 at 8:41 pm

NUTLEY, N.J., April 10, 2020 /PRNewswire/ --Researchers and clinical experts at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, are looking into the blood of COVID-19 survivors, as a potential treatment for current COVID-19 patients.

The work will scrutinize the antibodies within the serum of the surviving patients, in an attempt to discover more about the disease, and perhaps develop new ways to fight it.

"I'm so proud of our robust and innovative response to this unprecedented global challenge, from our front-line care teams to our support staff, and our exceptional researchers," said Robert C. Garrett, FACHE, chief executive officer of Hackensack Meridian Health. "Our scientists have been at the forefront of the latest innovations, including developing our own test and taking part in clinical trials of antiviral drugs. Now they're taking a leadership role in this advanced antibody work, which could prove to be a breakthrough."

"It really is a race against time," said Michele Donato, M.D., FACP, CPE, chief of stem cell transplantation and cellular therapy at John Theurer Cancer Center, part of Hackensack University Medical Center, and who is leading the potential treatment part of the work. "People are getting sick right now, and we are working night and day to save as many lives as possible."

Convalescent plasma treatments have previously been used to fight other viral outbreaks, including those of severe acute respiratory syndrome (SARS), caused by a virus that's a cousin to the one responsible for COVID-19, and which sickened thousands in 2002-2003.

At Hackensack Meridian Health, the researchers will first seek a small blood sample from those recovered or recovering patients who volunteer for the study, with the goal of finding those who developed the highest levels of targeted antibodies in response to the virus.

Those patients with the highest level of antibodies will be asked to return to provide a larger plasma donation, which may be utilized to infuse into very sick COVID-19 patients.

Taking part in this work will be experts from Hackensack Meridian John Theurer Cancer Center including Donato, who are experts in stem cell transplantation and cellular therapy, as well as scientists from Hackensack Meridian Health Center for Discovery and Innovation (CDI), who have developed a high-titer test to assess the presence and levels of the antibodies. The CDI also previously developed a diagnostic test for detecting the virus which has been used to diagnose more than a thousand patients so far in the Hackensack Meridian Heath network.

"This is applied science in 'real-time,' as this pandemic continues to spread," said David S. Perlin, Ph.D., the chief scientific officer and senior vice president of the CDI. "Our scientists at the CDI are responding to needs, and we're hoping to save lives."

"Research at Hackensack Meridian Health is more important than ever, and we are hopeful it will give us the edge against this pandemic," said Ihor Sawczuk, M.D., FACS, president of Hackensack MeridianHealth'sNorthern Market, and the chief research officer of the network.

The patients sought for the studies will be between the ages of 18 and 60, and have a prior laboratory diagnosis of COVID-19. They must also be at least 14 days without symptoms, according to the guidelines.

Potential donors can fill out an online form available here for the initial screening.

ABOUTHACKENSACKMERIDIAN HEALTH

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two children's hospitals - Joseph M. Sanzari Children's Hospital in Hackensack, K. Hovnanian Children's Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 34,100 team members, and 6,500 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The network's notable distinctions include having four hospitals among the top 10 in New Jersey by U.S. News and World Report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Becker's Healthcare's "150 Top Places to Work in Healthcare/2019" list.

The Hackensack Meridian School of Medicine at Seton Hall University, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

For additional information, please visit http://www.HackensackMeridianHealth.org.

About the Center for Discovery and Innovation

The Center for Discovery and Innovation, a newly established member of Hackensack Meridian Health, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions. The CDI, housed in a fully renovated state-of-the-art facility, offers world-class researchers a support infrastructure and culture of discovery that promotes science innovation and rapid translation to the clinic.

About John Theurer Cancer Center at Hackensack University Medical Center

John Theurer Cancer Center at Hackensack University Medical Center is New Jersey's largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey.John Theurer Cancer Center is amember of the Georgetown Lombardi Comprehensive Cancer Center Consortium,one of just 16 NCI-approved cancer research consortiabased at the nation's most prestigious institutions. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities.For additional information, please visitwww.jtcancercenter.org.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hackensack-meridian-health-studying-the-blood-of-covid-19-survivors-301038764.html

SOURCE Hackensack Meridian Health

The rest is here:
Hackensack Meridian Health Studying the Blood of COVID-19 Survivors - P&T Community

Posted in Stem Cell Research | Comments Off on Hackensack Meridian Health Studying the Blood of COVID-19 Survivors – P&T Community

What’s the best COVID-19 treatment? Science *real* science will tell us – Patheos

Posted: April 11, 2020 at 8:41 pm

Erlenmeyer Laboratory Chemistry Science Flasks, from http://maxpixel.freegreatpicture.com/Erlenmeyer-Laboratory-Chemistry-Science-Flasks-606611

Is hydroxychloroquine an effective treatment for COVID-19*?

Are ventilators effective in treating patients as the disease worsens?

Why are African-Americans dying in greater numbers?

Lets talk science.

How many times have you heard the phrase the science is settled? Thats been repeated endlessly with respect to climate change, but, in fact, the reality of science is that it is never settled.

Many years ago, as a student of history, I had a class in historiography in which the professor aimed to provide readings that would broaden the students understanding in a wider way than merely instruction in research methods. We read about Cargo Cults in a book called Cows, Pigs, Wars, and Witches, and we read about paradigm shifts in the classic The Structure of Scientific Revolutions, by Thomas Kuhn. (Yes, reader, when I read the book, I believed the word was pronounced para-dig-m instead of para-dime.) Heres how Wikipedia summarizes his argument:

Kuhn challenged the then prevailing view of progress in science in which scientific progress was viewed as development-by-accumulation of accepted facts and theories. Kuhn argued for an episodic model in which periods of conceptual continuity where there is cumulative progress, which Kuhn referred to as periods of normal science, were interrupted by periods of revolutionary science. The discovery of anomalies during revolutions in science leads to new paradigms. New paradigms then ask new questions of old data, move beyond the mere puzzle-solving of the previous paradigm, change the rules of the game and the map directing new research.

And permit me to cite two examples from medical research outside the coronavirus.

First, stem cell transplants for breast cancer.

Back, well, when the internet was in its infancy and one learned about news through actual newspapers, I recall reading about stem cell transplants, then watching the process play out for a relative of a friend, who was diagnosed with breast cancer and, as it advanced, treated with a stem cell transplant for those who dont recall, this was a method in which the patients stem cells were removed, then the patient received extremely high doses of chemotherapy, to completely kill the cancer but, as a consequence, destroying the immune system, and then the stem cells were re-infused. The risks of the procedure were great but it was believed that the reward was greater but, as it happened, my friends relative died. Now, doctors were so convinced of the efficacy of the treatment that insurance companies were pressured to cover it despite its experimental nature, and that the usual protocols of randomized controlled trials (RCT) were not followed because, after all, to deny half a test population a lifesaving treatment would consign them unfairly to death.

You may know the end of the story: when a RCT was finally conducted in 2000, it found that this procedure actually offered patients no benefit compared to conventional treatment. (You can read the whole story at Health Affairs.)

Second, research into Alzheimers Disease, and, more specifically, the amyloid hypothesis, that is, the theory that sticky brain plaques cause Alzheimers and that removing or preventing those plaques will cure or prevent the disease.

This theory became entrenched in the research for Alzheimers; a video at STAT describes the manner in which researchers moved from one failed drug trial to the next based on this theory. But heres an editorial at that publication from April of 2019:

If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimers disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials targeting amyloid protein in the brain as the cause of Alzheimers disease have failed. Its long past time to take a new approach to this mind-robbing disease. . . .

A comfortable partnership developed between believers in the amyloid hypothesis, funding agencies, and drug companies, so that only programs supporting this hypothesis were funded. Even today, the largest amount of NIH funding for Alzheimers disease research goes to amyloid-0related research.

Following the advice of their academic advisers most of them members of the amyloid cabal drug companies dutifully developed drugs to target amyloid with the goal of treating Alzheimers disease. Thy believed it was only a matter of time before the Alzheimers problem was solved. . . .

Other ideas were starved of funding or greeted with polite rolling of the eyes. . . .

This is a good place to talk about groupthink, the psychological phenomenon that occurs within a group of people in which the desire for harmony or conformity results in irrational or dysfunctional decision-making. Groupthink describes the funding and execution of Alzheimers disease research and drug development over the last 30 years. Once amyloid became the target, all other ideas were abandoned, shunned, even ridiculed. Although I believe that this dark period is behind us, weve wasted three decades and billions of dollars.

Trump is promoting the possible use of hydroxychloroquine as a treatment for the disease. Is he doing so recklessly? Are naysayers naysaying for scientific grounds or anti-Trump grounds?

One of the key issues is that there have not yet been RCTs for this treatment. In a disease such as COVID-19, where the large majority of people do recover, one way or the other, touting one treatment or another as a breakthrough without following a protocol of a control group cannot produce valid results, but here the French doctor who has been promoting this treatment, in combination with azithromycin, Didier Raoult, has been doing exactly this, by claiming that his treatment is so clearly successful that it would unethical to deny it to his patients. (See this Forbes article for a distillation of the debate, and a Q&A at The Hospitalist for some further scholarly comments.)

But hydroxychloroquine is not the only aspect of the pandemic where conventional wisdom and science are at odds.

Second, ventilators: heres a report from STAT on April 8th: With ventilators running out, doctors say the machines are overused for Covid-19.

Even as hospitals and governors raise the alarm about a shortage of ventilators, some critical care physicians are questioning the widespread use of the breathing machines for Covid-19 patients, saying that large numbers of patients could instead be treated with less intensive respiratory support.

If the iconoclasts are right, putting coronavirus patients on ventilators could be of little benefit to many and even harmful to some.

Whats driving this reassessment is a baffling observation about Covid-19: Many patients have blood oxygen levels so low they should be dead. But theyre not gasping for air, their hearts arent racing, and their brains show no signs of blinking off from lack of oxygen.

That is making critical care physicians suspect that blood levels of oxygen, which for decades have driven decisions about breathing support for patients with pneumonia and acute respiratory distress, might be misleading them about how to care for those with Covid-19. In particular, more and more are concerned about the use of intubation and mechanical ventilators. They argue that more patients could receive simpler, noninvasive respiratory support, such as the breathing masks used in sleep apnea, at least to start with and maybe for the duration of the illness.

This is not just a matter of trying to save money or resources by minimizing the use of ventilators. As the article reports, ventilation can actually cause harm: Older patients who do survive risk permanent cognitive and respiratory damage from being on heavy sedation for many days if not weeks and from the intubation.

And patients with COVID-19 who are placed on ventilators have an extremely high fatality rate: in one instance, 30 of 37 patients placed on mechanical ventilation died within a month. In another, only one out of seven patients older than 70, placed on a ventilator, survived.

Whats more,

one of the most severe consequences of Covid-19 suggests another reason the ventilators arent more beneficial. In acute respiratory distress syndrome, which results from immune cells ravaging the lungs and kills many Covid-19 patients, the air sacs of the lungs become filled with a gummy yellow fluid. That limits oxygen transfer from the lungs to the blood even when a machine pumps in oxygen, [Harvard Medical School physician Dr. Muriel] Gillick said.

All of which leads to the question: should RCTs be conducted for the treatment of using ventilators for COVID-19, rather than doctors assuming that this is an effective treatment because it is used for other respiratory diseases?

And, finally, heres a highly speculative observation coming out of a Facebook group:-thalassaemia (or beta-thalassaemia, or thalassemia without the ae) is a blood disorder which is connected to anemia. (Heres a lay description of the disorder.) This disorder is inherited, and the mild form causes no health issues so that carriers will pass on the disorder; it is common in the Mediterranean and the Middle East in the same manner as sickle-cell anemia is found in Africa and among individuals with African ancestry; in both cases, the mild form of the trait conferred protection against malaria.

What does this have to do with anything? Thalassaemia is prevalent in the Po valley, which is the region in northern Italy which is being hardest hit by COVID-19. At the same time, within the US, blacks (that is, people of African descent) are disproportionately likely to die of COVID-19. Within the US, this is being explained as due to socioeconomic disparities in that population and there clearly are significant disparities but is the paradigm that all health disparities are caused by socioeconomic disparities because race is only a social construct preventing researchers from identifying physiological differences, and, as a result, limiting scientists understanding of how to treat the disease?

In any event, the more I read, the stronger I feel that the answer to the search for a treatment for coronavirus will hinge on our scientists ability to look beyond groupthink and get at the basic science that underlies the disease, whatever that may be.

*Look, Id love to call it the Wuhan Virus, the Chinese Flu, or any other such phrase that communicates the role that China played in causing/exacerbating the pandemic, and I quite like the backronym, or alternative acronym, China-originated virus in December 19 (rather than COronaVIrus Disesase), but, lets face it, we need a common nomenclature.

More here:
What's the best COVID-19 treatment? Science *real* science will tell us - Patheos

Posted in Stem Cell Research | Comments Off on What’s the best COVID-19 treatment? Science *real* science will tell us – Patheos

Stem Cells Market Expected to Boost the Global Industry Growth in the Near Future – Germany English News

Posted: April 11, 2020 at 8:41 pm

Advance Market Analyticsreleased the research report ofGlobal Stem CellsMarket, offers a detailed overview of the factors influencing the global business scope.Global Stem Cells Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Stem Cells.This Report covers the emerging players data, including: competitive situation, sales, revenue and global market.

Free Sample Report + All Related Graphs & Charts @ https://www.advancemarketanalytics.com/sample-report/72815-global-stem-cells-market-1

The stem cell is used for treating chronic diseases such as cardiovascular disorders, cancer, diabetes, and others. Growing research and development in stem cell isolation techniques propelling market growth. For instance, a surgeon from Turkey developed a method for obtaining stem cells from the human body without enzymes which are generally used for the isolation of stem cells. Further, growing healthcare infrastructure in the developing economies and government spending on the life science research and development expected to drive the demand for stem cell market over the forecasted period.

The Global Stem Cellsis segmented by following Product Types:

Type (Adult Stem Cells (Neuronal, Hematopoietic, Mesenchymal, Umbilical Cord, Others), Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells, Very Small Embryonic-Like Stem Cells), Application (Regenerative Medicine (Neurology, Orthopedics, Oncology, Hematology, Cardiovascular and Myocardial Infraction, Injuries, Diabetes, Liver Disorder, Incontinence, Others), Drug Discovery and Development), Technology (Cell Acquisition (Bone Marrow Harvest, Umbilical Blood Cord, Apheresis), Cell Production (Therapeutic Cloning, In-vitro Fertilization, Cell Culture, Isolation), Cryopreservation, Expansion and Sub-Culture), Therapy (Autologous, Allogeneic)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.Enquire for customization in Report @:https://www.advancemarketanalytics.com/enquiry-before-buy/72815-global-stem-cells-market-1

Strategic Points Covered in Table of Content of Global Stem Cells Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Global Stem Cells market

Chapter 2: Exclusive Summary the basic information of the Global Stem Cells Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Global Stem Cells

Chapter 4: Presenting the Global Stem Cells Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying the by Type, End User and Region 2013-2018

Chapter 6: Evaluating the leading manufacturers of the Global Stem Cells market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Global Stem Cells Market is a valuable source of guidance for individuals and companies.

Data Sources & Methodology

The primary sources involves the industry experts from the Global Stem Cells Market including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Companys Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

Get More Information: https://www.advancemarketanalytics.com/reports/72815-global-stem-cells-market-1

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:

Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies revenues.

Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

Contact Us:

Craig Francis (PR & Marketing Manager)AMA Research & Media LLPUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us athttps://www.linkedin.com/company/advance-market-analyticshttps://www.facebook.com/AMA-Research-Media-LLP-344722399585916https://twitter.com/amareport

See the article here:
Stem Cells Market Expected to Boost the Global Industry Growth in the Near Future - Germany English News

Posted in Stem Cell Research | Comments Off on Stem Cells Market Expected to Boost the Global Industry Growth in the Near Future – Germany English News

Stem Cell Therapy Market Size 2020 | Top Companies, Growth Overview, Technology, Latest Trends and Forecast 2026 – Curious Desk

Posted: April 11, 2020 at 8:41 pm

New Jersey, United States:The new report has been added by Verified Market Research to provide a detailed overview of the Stem Cell Therapy Market. The study will help to better understand the Stem Cell Therapy industry competitors, the sales channel, Stem Cell Therapy growth potential, potentially disruptive trends, Stem Cell Therapy industry product innovations and the value / volume of size market (regional / national level, Stem Cell Therapy- Industrial segments), market share of the best actors / products.

Information has been added to the report to provide a realistic view of the industry based on data from Stem Cell Therapy manufacturers, i.e. H. Shipping, price, sales, gross profit, business distribution, etc., SWOT analysis, consumer preference, current developments and trends, drivers and limiting factors, company profile, investment opportunities, analysis of the demand gap, market size value / volume, services and products, Porters five models , socio-economic factors, official regulations in the Stem Cell Therapy branch. Market participants can use the report to take a look at the future of the Stem Cell Therapy market and make significant changes to their operating style and marketing tactics in order to achieve sustainable growth.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=CDN&utm_medium=003

The report examines the competitive environment scenario observed with key players in Stem Cell Therapy sales, the profile of their business, their earnings, their sales, their business tactics, and the forecasting situations of the Stem Cell Therapy sales industry. According to studies, the Stem Cell Therapy sales market is very competitive and diverse due to global and local suppliers.

The Stem Cell Therapy Sales Market Report mainly contains the following Manufacturers:

Market Competition

The competitive landscape of the Stem Cell Therapy market is examined in detail in the report, with a focus on the latest developments, the future plans of the main players and the most important growth strategies that they have adopted. The analysts who compiled the report have created a portrait of almost all of the major players in the Stem Cell Therapy market, highlighting their key commercial aspects such as production, areas of activity and product portfolio. All companies analyzed in the report are examined on the basis of important factors such as market share, market growth, company size, production, sales and earnings.

Report Highlights

Assessment of sales channels

innovation trends

sustainability strategies

Niche market trends

Market entry analysis

market size and forecast

The geographic department provides data that give you an overview of the turnover of companies and sales figures for the growth activity Stem Cell Therapy for electrical meters. Here are the strengths of the geographic divisions: North America (United States, Canada and Mexico), Europe (Germany, Spain, France, Great Britain, Russia and Italy and more), Asia-Pacific (China, Japan, Korea, India and Southeast Asia) and more ), South America (Brazil, Argentina, Colombia), the Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa) and ROW.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=CDN&utm_medium=003

Table of Content

1 Introduction of Stem Cell Therapy Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology 3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model5.1 Overview

6 Stem Cell Therapy Market, By Solution6.1 Overview

7 Stem Cell Therapy Market, By Vertical7.1 Overview

8 Stem Cell Therapy Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=CDN&utm_medium=003

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

More here:
Stem Cell Therapy Market Size 2020 | Top Companies, Growth Overview, Technology, Latest Trends and Forecast 2026 - Curious Desk

Posted in Stem Cell Research | Comments Off on Stem Cell Therapy Market Size 2020 | Top Companies, Growth Overview, Technology, Latest Trends and Forecast 2026 – Curious Desk

COVID-19 Impact on Stem Cell Media Market Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 -…

Posted: April 11, 2020 at 8:41 pm

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Stem Cell Media Market which would mention How the Covid-19 is Affecting the Stem Cell Media Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Stem Cell Media Players to Combat Covid-19 Impact.

The Global Stem Cell Media Market has been garnering remarkable momentum in the recent years. The steadily escalating demand due to improving purchasing power is projected to bode well for the global market. QY Researchs latest publication, Titled [Stem Cell Media Market Research Report 2020], offers an insightful take on the drivers and restraints present in the market. It assesses the historical data pertaining to the global Stem Cell Media market and compares it to the current market trends to give the readers a detailed analysis of the trajectory of the market. A team subject-matter experts have provided the readers a qualitative and quantitative data about the market and the various elements associated with it.

Global Stem Cell Media Market is valued at USD XX million in 2020 and is projected to reach USD XX million by the end of 2026, growing at a CAGR of XX% during the period 2020 to 2026.

Top Key Players of the Global Stem Cell Media Market:Thermo Fisher, STEMCELL Technologies, Merck Millipore, Lonza, GE Healthcare, Miltenyi Biotec, Corning, CellGenix, Takara, PromoCell, HiMedia

>>Get Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures):https://www.qyresearch.com/sample-form/form/1637298/global-stem-cell-media-market

The Essential Content Covered in the Global Stem Cell Media Market Report:Top Key Company Profiles.Main Business and Rival InformationSWOT Analysis and PESTEL AnalysisProduction, Sales, Revenue, Price and Gross MarginMarket Size And Growth RateCompany Market Share

Global Stem Cell Media Market Segmentation By Product:Pluripotent Stem Cell Culture, Hematopoietic Stem Cell Culture, Mesenchymal Stem Cell Culture, Others

Global Stem Cell Media Market Segmentation By Application:Scientific Research, Industrial Production

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Stem Cell Media Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets.Stem Cell Media Market in South, America region is also expected to grow in near future.

Key questions answered in the report*What will be the market size in terms of value and volume in the next five years?*Which segment is currently leading the market?*In which region will the market find its highest growth?*Which players will take the lead in the market?*What are the key drivers and restraints of the markets growth?

>>>Request Customization of Report :https://www.qyresearch.com/customize-request/form/1637298/global-stem-cell-media-market

Table of Content

1 Stem Cell Media Market Overview1.1 Stem Cell Media Product Overview1.2 Stem Cell Media Market Segment by Type1.2.1 Pluripotent Stem Cell Culture1.2.2 Hematopoietic Stem Cell Culture1.2.3 Mesenchymal Stem Cell Culture1.2.4 Others1.3 Global Stem Cell Media Market Size by Type (2015-2026)1.3.1 Global Stem Cell Media Market Size Overview by Type (2015-2026)1.3.2 Global Stem Cell Media Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Stem Cell Media Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Stem Cell Media Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Stem Cell Media Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Stem Cell Media Market Size Forecast by Type (2021-2026)1.3.3.1 Global Stem Cell Media Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Stem Cell Media Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Stem Cell Media Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.2 Europe Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.4 Latin America Stem Cell Media Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Stem Cell Media Sales Breakdown by Type (2015-2026)1.5 Coronavirus Disease 2019 (Covid-19): Stem Cell Media Industry Impact1.5.1 How the Covid-19 is Affecting the Stem Cell Media Industry1.5.1.1 Stem Cell Media Business Impact Assessment Covid-191.5.1.2 Supply Chain Challenges1.5.1.3 COVID-19s Impact On Crude Oil and Refined Products1.5.2 Market Trends and Stem Cell Media Potential Opportunities in the COVID-19 Landscape1.5.3 Measures / Proposal against Covid-191.5.3.1 Government Measures to Combat Covid-19 Impact1.5.3.2 Proposal for Stem Cell Media Players to Combat Covid-19 Impact

2 Global Stem Cell Media Market Competition by Company2.1 Global Top Players by Stem Cell Media Sales (2015-2020)2.2 Global Top Players by Stem Cell Media Revenue (2015-2020)2.3 Global Top Players Stem Cell Media Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Stem Cell Media Manufacturing Base Distribution, Sales Area, Product Type2.5 Stem Cell Media Market Competitive Situation and Trends2.5.1 Stem Cell Media Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Stem Cell Media Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Media as of 2019)2.7 Date of Key Manufacturers Enter into Stem Cell Media Market2.8 Key Manufacturers Stem Cell Media Product Offered2.9 Mergers & Acquisitions, Expansion

3 Global Stem Cell Media Status and Outlook by Region (2015-2026)3.1 Global Stem Cell Media Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Stem Cell Media Market Size Market Share by Region (2015-2020)3.2.1 Global Stem Cell Media Sales Market Share by Region (2015-2020)3.2.2 Global Stem Cell Media Revenue Market Share by Region (2015-2020)3.2.3 Global Stem Cell Media Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Stem Cell Media Market Size Market Share by Region (2021-2026)3.3.1 Global Stem Cell Media Sales Market Share by Region (2021-2026)3.3.2 Global Stem Cell Media Revenue Market Share by Region (2021-2026)3.3.3 Global Stem Cell Media Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Stem Cell Media Market Size YoY Growth (2015-2026)3.4.1 North America Stem Cell Media Revenue YoY Growth (2015-2026)3.4.2 North America Stem Cell Media Sales YoY Growth (2015-2026)3.5 Asia-Pacific Stem Cell Media Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Stem Cell Media Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Stem Cell Media Sales YoY Growth (2015-2026)3.6 Europe Stem Cell Media Market Size YoY Growth (2015-2026)3.6.1 Europe Stem Cell Media Revenue YoY Growth (2015-2026)3.6.2 Europe Stem Cell Media Sales YoY Growth (2015-2026)3.7 Latin America Stem Cell Media Market Size YoY Growth (2015-2026)3.7.1 Latin America Stem Cell Media Revenue YoY Growth (2015-2026)3.7.2 Latin America Stem Cell Media Sales YoY Growth (2015-2026)3.8 Middle East and Africa Stem Cell Media Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Stem Cell Media Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Stem Cell Media Sales YoY Growth (2015-2026)

4 Global Stem Cell Media by Application4.1 Stem Cell Media Segment by Application4.1.1 Scientific Research4.1.2 Industrial Production4.2 Global Stem Cell Media Sales by Application: 2015 VS 2020 VS 20264.3 Global Stem Cell Media Historic Sales by Application (2015-2020)4.4 Global Stem Cell Media Forecasted Sales by Application (2021-2026)4.5 Key Regions Stem Cell Media Market Size by Application4.5.1 North America Stem Cell Media by Application4.5.2 Europe Stem Cell Media by Application4.5.3 Asia-Pacific Stem Cell Media by Application4.5.4 Latin America Stem Cell Media by Application4.5.5 Middle East and Africa Stem Cell Media by Application5 North America Stem Cell Media Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Stem Cell Media Sales Market Share by Country (2015-2020)5.1.2 North America Stem Cell Media Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Stem Cell Media Sales Market Share by Country (2021-2026)5.2.2 North America Stem Cell Media Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Stem Cell Media Market Size YoY Growth (2015-2026)5.3.2 Canada Stem Cell Media Market Size YoY Growth (2015-2026)6 Europe Stem Cell Media Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Stem Cell Media Sales Market Share by Country (2015-2020)6.1.2 Europe Stem Cell Media Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Stem Cell Media Sales Market Share by Country (2021-2026)6.2.2 Europe Stem Cell Media Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Stem Cell Media Market Size YoY Growth (2015-2026)6.3.2 France Stem Cell Media Market Size YoY Growth (2015-2026)6.3.3 U.K. Stem Cell Media Market Size YoY Growth (2015-2026)6.3.4 Italy Stem Cell Media Market Size YoY Growth (2015-2026)6.3.5 Russia Stem Cell Media Market Size YoY Growth (2015-2026)7 Asia-Pacific Stem Cell Media Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Stem Cell Media Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Stem Cell Media Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Stem Cell Media Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Stem Cell Media Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Stem Cell Media Market Size YoY Growth (2015-2026)7.3.2 Japan Stem Cell Media Market Size YoY Growth (2015-2026)7.3.3 South Korea Stem Cell Media Market Size YoY Growth (2015-2026)7.3.4 India Stem Cell Media Market Size YoY Growth (2015-2026)7.3.5 Australia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.6 Taiwan Stem Cell Media Market Size YoY Growth (2015-2026)7.3.7 Indonesia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.8 Thailand Stem Cell Media Market Size YoY Growth (2015-2026)7.3.9 Malaysia Stem Cell Media Market Size YoY Growth (2015-2026)7.3.10 Philippines Stem Cell Media Market Size YoY Growth (2015-2026)7.3.11 Vietnam Stem Cell Media Market Size YoY Growth (2015-2026)8 Latin America Stem Cell Media Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Stem Cell Media Sales Market Share by Country (2015-2020)8.1.2 Latin America Stem Cell Media Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Stem Cell Media Sales Market Share by Country (2021-2026)8.2.2 Latin America Stem Cell Media Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Stem Cell Media Market Size YoY Growth (2015-2026)8.3.2 Brazil Stem Cell Media Market Size YoY Growth (2015-2026)8.3.3 Argentina Stem Cell Media Market Size YoY Growth (2015-2026)9 Middle East and Africa Stem Cell Media Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Stem Cell Media Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Stem Cell Media Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Stem Cell Media Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Stem Cell Media Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Stem Cell Media Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Stem Cell Media Market Size YoY Growth (2015-2026)9.3.3 UAE Stem Cell Media Market Size YoY Growth (2015-2026)

10 Company Profiles and Key Figures in Stem Cell Media Business10.1 Thermo Fisher10.1.1 Thermo Fisher Corporation Information10.1.2 Thermo Fisher Description, Business Overview and Total Revenue10.1.3 Thermo Fisher Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.1.4 Thermo Fisher Stem Cell Media Products Offered10.1.5 Thermo Fisher Recent Development10.2 STEMCELL Technologies10.2.1 STEMCELL Technologies Corporation Information10.2.2 STEMCELL Technologies Description, Business Overview and Total Revenue10.2.3 STEMCELL Technologies Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.2.4 Thermo Fisher Stem Cell Media Products Offered10.2.5 STEMCELL Technologies Recent Development10.3 Merck Millipore10.3.1 Merck Millipore Corporation Information10.3.2 Merck Millipore Description, Business Overview and Total Revenue10.3.3 Merck Millipore Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.3.4 Merck Millipore Stem Cell Media Products Offered10.3.5 Merck Millipore Recent Development10.4 Lonza10.4.1 Lonza Corporation Information10.4.2 Lonza Description, Business Overview and Total Revenue10.4.3 Lonza Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.4.4 Lonza Stem Cell Media Products Offered10.4.5 Lonza Recent Development10.5 GE Healthcare10.5.1 GE Healthcare Corporation Information10.5.2 GE Healthcare Description, Business Overview and Total Revenue10.5.3 GE Healthcare Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.5.4 GE Healthcare Stem Cell Media Products Offered10.5.5 GE Healthcare Recent Development10.6 Miltenyi Biotec10.6.1 Miltenyi Biotec Corporation Information10.6.2 Miltenyi Biotec Description, Business Overview and Total Revenue10.6.3 Miltenyi Biotec Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.6.4 Miltenyi Biotec Stem Cell Media Products Offered10.6.5 Miltenyi Biotec Recent Development10.7 Corning10.7.1 Corning Corporation Information10.7.2 Corning Description, Business Overview and Total Revenue10.7.3 Corning Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.7.4 Corning Stem Cell Media Products Offered10.7.5 Corning Recent Development10.8 CellGenix10.8.1 CellGenix Corporation Information10.8.2 CellGenix Description, Business Overview and Total Revenue10.8.3 CellGenix Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.8.4 CellGenix Stem Cell Media Products Offered10.8.5 CellGenix Recent Development10.9 Takara10.9.1 Takara Corporation Information10.9.2 Takara Description, Business Overview and Total Revenue10.9.3 Takara Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.9.4 Takara Stem Cell Media Products Offered10.9.5 Takara Recent Development10.10 PromoCell10.10.1 Company Basic Information, Manufacturing Base and Competitors10.10.2 Stem Cell Media Product Category, Application and Specification10.10.3 PromoCell Stem Cell Media Sales, Revenue, Price and Gross Margin (2015-2020)10.10.4 Main Business Overview10.10.5 PromoCell Recent Development10.11 HiMedia10.11.1 HiMedia Corporation Information10.11.2 HiMedia Description, Business Overview and Total Revenue10.11.3 HiMedia Stem Cell Media Sales, Revenue and Gross Margin (2015-2020)10.11.4 HiMedia Stem Cell Media Products Offered10.11.5 HiMedia Recent Development

11 Stem Cell Media Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Stem Cell Media Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers 11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Stem Cell Media Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis

12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers

13 Research Findings and Conclusion

14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Original post:
COVID-19 Impact on Stem Cell Media Market Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 -...

Posted in Stem Cell Research | Comments Off on COVID-19 Impact on Stem Cell Media Market Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 -…

Why Choose Us – Pennsylvania Stem Cell Center

Posted: April 10, 2020 at 10:47 am

Why Dr. Thomas E. Young?

Pennsylvania Stem Cell Centers, with three offices in the greater Philadelphia region, is a leading and innovative provider of adult stem cell therapies in Pennsylvania. Working as an affiliate of the Cell Surgical Network (the worlds largest regenerative medicine clinical research organization), Dr. Thomas E. Young is committed to helping patients who suffer from degenerative and inflammatory conditions. Therapies using ones own stem cells may be the next great advancement in medicine.

Because Pennsylvania Stem Cell Centers only uses adult stem cells harvested directly from the patients own fat stores, an extremely high number of stem cells are usually available almost immediately. Regenerative healing naturally takes time and we do not expect immediate improvement in symptoms. Patients will be followed closely through our research registry and data, carefully collected to help establish effectiveness of our protocols.

Stem Cell Therapy is used to promote the repair of degenerative or injured tissue by harnessing the natural healing power of mesenchymal stem cells that form the musculoskeletal tissues in the body including bone, joint cartilage, ligaments, and tendons. The mission at PA Stem Cell Treatment Centers is to promote natural healing using autologous cellular therapies for the cure and treatment of musculoskeletal disorders, to relieve pain, and to improve functionality and quality of life.

PA Stem Cell Treatment Centers is highly committed to clinical research and the advancement of regenerative medicine.

Read this article:
Why Choose Us - Pennsylvania Stem Cell Center

Posted in Pennsylvania Stem Cells | Comments Off on Why Choose Us – Pennsylvania Stem Cell Center

Moderna: A $12 Billion Brand Built On Hope And mRNA – Seeking Alpha

Posted: April 10, 2020 at 10:47 am

Moderna (MRNA) put mRNA technology on the map, however, this technology has not yet proven itself convincingly in clinical trials. The concept of making your own body behave like a drug manufacturing engine is interesting, but it has its hurdles. One hurdle is the body's own immune system, which may reject the mRNA; the other is whether the technology will produce enough proteins to make a difference - with the human body, you never know what will trigger a cascade of unpredictable events that could foil the "best laid plans of men," however smart. Delivery into cells is another issue. Everything always boils down to human trials - and here, Moderna is not there yet.

Most of the biotech investing rules I follow tell me Moderna is an absolute avoid. One, a $12bn market valuation based on a pipeline of near 20 candidates. These are based on a single all-curing drug platform. Not a single drug candidate is beyond phase 2. Two, the current price of the one-year old IPO is at 52-week and all time highs based on a fear and hope around a sudden pandemic like coronavirus. Three, a corollary of point one, there is little phase 2 efficacy data anywhere, therefore the platform, however promising, is absolutely unproven. However, on the other hand, another critical business rule I also follow is "follow the cash," and this early stage biopharma has $2bn of it. This is more cash than the entire current market cap of a company like Amarin (AMRN) with an approved and blockbuster potential product.

In order to understand this anomaly, I looked into the science behind the company, because the valuation of a pre-market pre-approval stage biopharma is mostly based on the science. And the science does look promising.

First, let us understand that the company says that mRNA-based therapeutic protein synthesis is the next step to recombinant protein technology, which has spawned an industry worth over $200bn. However, recombinant technology cannot create certain major types of proteins - intracellular and membrane proteins which represent as much as two-thirds of the proteins in humans. This is a major part of what mRNA technology can do.

There are various competitive advantages to mRNA over recombinance - for one, since the proteins are made naturally, there's less chance of rejection and immunogenicity. Another advantage, as the company says, "A vast number of potential mRNA medicines can be developed, therefore, with only minor changes to the underlying chemical structure of the molecule or manufacturing processes, a significant advantage over small molecule or protein therapeutics."

Moderna was founded in 2010 and IPO-ed in late 2018. Reading through the 10-K, what struck me was that there's a huge number of programs, all of them early stages, each demonstrating, to some extent, the development of critical antibodies upon using the drug candidate. However, instead of developing any particular program to fruition, including BLA and approval, this company focuses on advancing the entire pipeline at the same time.

Here's a snapshot of the pipeline:

Source

Next, let me present a set of 6 slides, each for one of the modalities above, which shows the latest available trial data for that drug candidate:-

Source - 10-K

Now, we have multiple programs progressing through phase 2 - which is really the datapoint that first gets us interested (or not) in a company. Then, just today, we read about the company's plans to start a phase 3 trial "soon." However, like we said, we still couldn't find enough that could justify this huge $11.8bn valuation. I mean, the science is good, in theory, but this sort of high-grade technology has so many pitfalls it really doesn't make sense to have too much expectation until we see phase 3 data.

The above 6 slides basically show that in the lab and in primates and in healthy subjects, there's constructive antibody activity on dosing with these mRNA medicines. Some of the measures of these activities are promising, for example, for mRNA-1944, "participants had measured antibody levels exceeding the levels of antibody expected to be protective against chikungunya infection (> 1 g/mL) following a single dose, with the middle and high doses projected to maintain antibody levels above protective levels for at least 16 weeks." But this was a phase 1 study in healthy volunteers, and while promising, like I said, this alone does not justify the valuation.

Sometimes, companies like these justify their valuations on the basis of their founders, or the founding technology; Juno comes to mind. Again, nothing like that was clearly apparent to me on reading either the 10-K or the Corporate Presentation. Besides a lot of basic and advanced genetic science, I could not figure out who is behind the science; admittedly, though, MRNA does have a vast patent estate comprising more than 550 patents worldwide, applied for and granted.

A much better overview of the history of the science is found here. There are basically five key figures behind it; the original science was developed by University of Pennsylvania scientist Katalin Karik, but her startup didn't go anywhere directly. "Later, in 2010 Harvard University scientist Derrick Rossi used modified mRNA to encode proteins that reprogrammed adult cells into embryonic-like stem cells. Harvard cardiovascular scientist Kenneth Chien, now at the Karolinska Institute, and Massachusetts Institute of Technologys famed serial entrepreneur Robert Langer spotted mRNAs therapeutic potential and joined Rossi in pitching a stem cell company to the venture capital firm Flagship Pioneering." This led to Moderna.

In recent times, under the coronavirus pandemic, Moderna has suppressed the rest of its pipeline and is focusing almost entirely on mRNA-1273, its candidate for treating COVID-19. Although mRNA can in theory target multiple types of diseases, vaccines are still their easiest application, since "the mRNA needs to produce only a small amount of protein for the vaccine to work, and setting off the bodys RNA immune sensors a little wont hurt." The company already had multiple viral vaccine targets under development, including one on MERS-COV in the lab, so it is understandable that a little tweak could set things off in coronavirus targeting.

From its press release, the latest that is happening in this regard is

On March 27, 2020, the NIH announced that Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in the NIH-led Phase 1 study of mRNA-1273.

According to a PR dated 4/7/2020, Moderna will host a virtual Vaccines Day for analysts and investors on 4/14/2020. The Vaccines Day will include presentations from Stphane Bancel, Chief Executive Officer, Tal Zaks, Chief Medical Officer, and key opinion leaders with a focus on mRNA vaccines and the Companys core prophylactic vaccines modality.

According to another PR dated 4/8/2020, Lorence Kim, M.D., the company's Chief Financial Officer, will participate in the 19th Annual Needham Healthcare Conference on 4/15/2020.

Currently, everything in this $12bn behemoth hinges around producing a working vaccine for SARS-COV-2. There are pitfalls - efficacy, timeline, positioning, market - that could determine how it all works out. Success or failure here could determine what happens to the company as a whole, because the market seems to be in an over-expectant mode right now.

In 2018, when the company IPO-ed, CEO Bancel said This is a 20-year job...We believe we are just starting. It seems to this author that $12bn is just a little too much to start with for something that may be promising, but still unproven. The science looks good - although there's a lot of secrecy behind it as of now - so if these prices go down for whatever reason, I would be much more interested. The company's vast and diverse collaborations - with AstraZeneca (NYSE:AZN), Merck (NYSE:MRK) and others - does build confidence that big pharma is looking at it favorably.

Thanks for reading. At the Total Pharma Tracker, we do more than follow biotech news. Using our IOMachine, our team of analysts work to be ahead of the curve.

That means that when the catalyst comes that will make or break a stock, we've positioned ourselves for success. And we share that positioning and all the analysis behind it with our members.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I own AMRN.

See more here:
Moderna: A $12 Billion Brand Built On Hope And mRNA - Seeking Alpha

Posted in Pennsylvania Stem Cells | Comments Off on Moderna: A $12 Billion Brand Built On Hope And mRNA – Seeking Alpha

Page 1,066«..1020..1,0651,0661,0671,068..1,0801,090..»